Plot No.367, Abhey Pur, Industrial Area Phase-1, Panchkula, Haryana 134109
Don't miss out on this limited-time offer to join our successful PCD Pharma network. Fill in your details below and our team will get in touch with you to discuss the best franchise opportunities tailored to your needs.
Olmesartan Medoxomil (40mg) tablet
Therapeutic Category
Cardiology, Cardiovascular
Dosage Form
Tablet
Packaging Type
Alu Alu
Packaging
10*10
Price
₹169/-
High-resolution images and Product visuals
Product overview and usage information
Detailed information and research documents
Olmeslide 40 Tablet contains Olmesartan Medoxomil 40 mg, an angiotensin II receptor blocker (ARB) used for effective management of high blood pressure (hypertension). It works by selectively blocking the binding of angiotensin II to the AT1 receptor in vascular smooth muscle, resulting in vasodilation and a reduction in blood pressure. Long-term control of hypertension with Olmesartan reduces the risk of stroke, heart attack, and kidney problems. It may be used alone or in combination with other antihypertensive agents.
Olmeslide 40 Tablet is generally well tolerated. Some patients may experience dizziness, headache, fatigue, or gastrointestinal disturbances like nausea. Rare side effects include hypotension, elevated potassium levels, and renal function impairment. Immediate medical attention should be sought if symptoms of allergic reaction or swelling occur.
Olmeslide 40 Tablet is indicated for the treatment of essential hypertension in adults. It is also used as part of combination therapy in cases where blood pressure is not adequately controlled by monotherapy. In some cases, it may be used to protect kidney function in patients with type 2 diabetes and proteinuria.
Olmeslide 40 Tablet should be taken exactly as prescribed by a healthcare professional. It is not recommended during pregnancy, especially in the second and third trimesters, due to the risk of fetal harm. Use with caution in patients with renal or hepatic impairment. Avoid use with potassium supplements or potassium-sparing diuretics unless advised by a physician.
Store at a temperature below 30°C, away from moisture and direct sunlight. Keep out of reach of children.
Composition : Olmesartan 20 mg + Hydrochlorothiazide 12.50 mg tablet
Composition : Olmesartan 40 mg + hydrochlorothiazide 12.50 mg tablet
Composition : Nitroglycerine 2.6 mg Tablet
Composition : Nitroglycerine 6.4 mg Tablet
Composition : Nicorandil (5mg) Tablet
Composition : Nicorandil 10 mg Tablet
Composition : Fenofibrate (145mg) tablet
Composition : Fenofibrate 160 mg tablet
Composition : Ezetimibe 10 mg tablet
Composition : Aspirin 75 mg + Rosuvastatin 20 mg + Clopidogrel 75 mg capsule
This catalog is a digital representation of the Cafoli Lifecare portfolio and is intended for use by authorized pharmaceutical distributors and PCD franchise partners.
Olmesartan Medoxomil 40 mg Tablet is a high-strength angiotensin II receptor blocker (ARB) used for the management of moderate to severe hypertension (high blood pressure). It works by relaxing blood vessels, improving blood flow, and providing effective long-term blood pressure control. This makes it a key product in the cardiology and antihypertensive segment, offering strong business potential for medical distributors, wholesalers, and pharma franchise partners in the PCD pharma franchise market.
Medical distributors and wholesalers can benefit from consistent demand from cardiologists, physicians, and general practitioners. Due to the increasing prevalence of hypertension and the need for long-term treatment, Olmesartan Medoxomil 40 mg ensures regular prescriptions, repeat purchases, and stable market growth opportunities.
Yes, Cafoli Lifecare offers PCD pharma franchise opportunities in the cardiac and antihypertensive segment with monopoly rights, quality-assured manufacturing standards, attractive promotional support, and reliable supply chain assistance for distributors and franchise partners.
Wholesalers and distributors benefit from strong prescription demand, long-term patient adherence, growing cardiovascular healthcare needs, and continuous institutional requirements, making this product a profitable and sustainable addition to their pharmaceutical portfolio when partnered with Cafoli Lifecare.
Medical distributors, stockists, and pharma professionals interested in antihypertensive and cardiovascular formulations can contact Cafoli Lifecare to discuss product availability, pricing structure, promotional support, and PCD pharma franchise opportunities in the cardiac segment.